We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$29B
$58.7M 1.23%
311,000
+11,000
+4% +$2.06M
EVH icon
27
Evolent Health
EVH
$444M
$58.1M 1.22%
1,875,000
+175,957
+10% +$4.22M
PCRX icon
28
Pacira BioSciences
PCRX
$974M
$56M 1.18%
1,000,000
-25,000
-2% -$1.44M
EXAS
29
DELISTED
Exact Sciences
EXAS
$54.4M 1.14%
570,000
– –
PRTA icon
30
Prothena Corp
PRTA
$468M
$50.6M 1.06%
710,430
-239,661
-25% -$14.9M
TFX icon
31
Teleflex
TFX
$5.89B
$49M 1.03%
130,000
– –
KRTX
32
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$47.9M 1.01%
391,917
+5,299
+1% +$612K
ARVN icon
33
Arvinas
ARVN
$588M
$47.5M 1%
577,500
-48,600
-8% -$4.3M
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$47.2M 0.99%
1,600,589
+583,644
+57% +$16.4M
SWAV
35
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$45.3M 0.95%
220,000
– –
ACHC icon
36
Acadia Healthcare
ACHC
$2.96B
$45.3M 0.95%
710,000
+10,000
+1% +$631K
VERV
37
DELISTED
Verve Therapeutics
VERV
$45.3M 0.95%
962,826
– –
KYMR icon
38
Kymera Therapeutics
KYMR
$9.03B
$43.1M 0.91%
732,927
+106,400
+17% +$6.17M
HCAT icon
39
Health Catalyst
HCAT
$127M
$42.5M 0.89%
850,000
+65,000
+8% +$3.55M
SGEN
40
DELISTED
Seagen Inc. Common Stock
SGEN
$42.5M 0.89%
250,000
– –
PEN icon
41
Penumbra
PEN
$12.8B
$39.3M 0.83%
147,500
– –
ACCD
42
DELISTED
Accolade Inc
ACCD
$38.9M 0.82%
923,000
+258,000
+39% +$12.1M
EHC icon
43
Encompass Health
EHC
$12.5B
$37.5M 0.79%
628,500
– –
TVTX icon
44
Travere Therapeutics
TVTX
$5.74B
$36.3M 0.76%
1,496,817
+2,653
+0.2% +$48.7K
BAX icon
45
Baxter International
BAX
$14.4B
$36.2M 0.76%
+450,000
New +$35.6M
WRBY icon
46
Warby Parker
WRBY
$3.26B
$34.5M 0.73%
+650,000
New +$35M
LENZ
47
LENZ Therapeutics
LENZ
$168M
$34M 0.72%
296,673
-10,718
-3% -$1.59M
XENT
48
DELISTED
Intersect ENT, Inc
XENT
$33.2M 0.7%
1,220,000
– –
SRPT icon
49
Sarepta Therapeutics
SRPT
$1.81B
$32.4M 0.68%
350,000
+21,250
+6% +$1.64M
ALLK
50
DELISTED
Allakos
ALLK
$32.4M 0.68%
305,706
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.